Investigating cellular interrelationships in spatial context helps researchers illuminate changes that may correlate with disease progression and therapeutic response.

Watch these seminars to learn how researchers are using the Hyperion™ Imaging System for tissue microenvironment characterization, biomarker discovery and more.

	Understanding the Immune Composition and Therapeutic Vulnerabilities of Human Lung Cancer Using Imaging Mass Cytometry Kurt Schalper, MD, PhD Assistant Professor of Pathology Director, Translational Immuno-Oncology Laboratory Yale Cancer Center Watch
	Uncovering Cellular Social Networks: Analysis of Tissue Ecosystems in Health and Disease by Imaging Mass Cytometry Bernd Bodenmiller, PhD  Assistant Professor, Institute of Molecular Life Sciences University of Zurich Watch
	Advancing Translational and Clinical Research: Imaging Mass Cytometry to Characterize the Tumor Immune Microenvironment Akil Merchant, MD  Assistant Professor of Medicine Keck School of Medicine University of Southern California Watch

For Research Use Only. Not for use in diagnostic procedures.

Imaging Mass Cytometry used to investigate tumor and blood microenvironments and tertiary lymphoid structure.

Hear Dr. Akil Merchant, MD, describe how research teams from the University of Southern California use Imaging Mass Cytometry™ to assess circulating tumor cells in the blood and analyze immune cells within the tumor microenvironment.

In this recorded live seminar, Merchant discusses:

• how Imaging Mass Cytometry was integrated with the HD-SCA assay to study the role of CTCs in prostate and breast cancer
• the simultaneous analysis of multiple markers to identify T^REG cells within the tumor microenvironment
• the characterization of immune infiltrate in Hodgkin’s lymphoma

Researchers in Merchant’s lab are investigating how tumor cells interact with their microenvironment and how this interaction contributes to the development and maintenance of cancer. They are studying how immune cells are trafficked into the tumor space and how immune cells can be harnessed to treat cancer. They are also interested in signaling pathways in cancer cells that confer resistance to chemotherapy. Merchant is a practicing hematologist and oncologist at USC Norris Comprehensive Cancer Center. He also participates in several clinical trials for patients with various cancers.

Akil Merchant, MD Assistant Professor of Medicine Keck School of Medicine University of Southern California

For Research Use Only. Not for use in diagnostic procedures.

Assessment of cell-to-cell interactions and the tissue ecosystem by Imaging Mass Cytometry supports the Bodenmiller lab’s goal of using precision medicine to revolutionize disease treatment.

Hear Bernd Bodenmiller, PhD, describe how this new approach provides researchers with an unprecedented view of complex cellular phenotypes and their relationships in the context of the tissue microenvironment.

In this recorded live seminar, Bodenmiller discusses:

• how Imaging Mass Cytometry™ empowers a multiplexed tissue view from molecules to morphology
• the development of histoCAT™ software and how it enables deep analysis of cell type and cellular social networks
• the use of Imaging Mass Cytometry to assess cellular heterogeneity and identify a variety of phenotypes in breast cancer samples
• an approach to profiling of tumor sphere cultures

Bodenmiller’s lab develops experimental and computational methods to unravel regulatory systems on the single-cell level that underlie cancer development. His group’s goal is to develop methods based on CyTOF® technology to quantitatively analyze trans-cellular circuits. Based on the mass cytometry data, they model and analyze how complex cell phenotypes in tumors are controlled, with the hope that this will enable targeted modulation that interferes with tumor development.

Learn more about Bernd Bodenmiller in this exclusive spotlight interview.

Bernd Bodenmiller, PhD Assistant Professor Institute of Molecular Life Sciences University of Zurich

For Research Use Only. Not for use in diagnostic procedures.

Mass cytometry expert Adeeb Rahman, PhD, describes the basics of mass cytometry and how it is used today to support the full service immune monitoring program at the Icahn School of Medicine at Mount Sinai.

In this recorded webinar, Rahman shares how he has successfully integrated deep immune profiling with mass cytometry into translational research in multiple disease areas including cancer, infectious disease and allergy, enabling immune landscape mapping and discovery of disease-specific immune cell signatures.

Michelle Poulin, PhD, of Fluidigm, describes the development of the Maxpar^® Human Immune Monitoring Panel Kit, designed to enable deep immune profiling of human PBMC in a single tube. Poulin presents an overview of the 29-marker mass cytometry panel as well as data showing repeatability, reproducibility and performance verification when the panel is used with frozen PBMC samples.

Speakers

Adeeb Rahman      
Assistant Professor   
Icahn School of Medicine at Mount Sinai

Michelle Poulin, PhD
Manager, Field Applications Proteomics  
Fluidigm

For Research Use Only. Not for use in diagnostic procedures.

Highly multiplex panels used to interrogate diverse immune populations and immuno-modulatory targets

Hear Dr. Kurt Schalper describe how research performed at the Translational Immuno-Oncology Laboratory at Yale Cancer Center uses Imaging Mass Cytometry™ (IMC™) as one way to open new opportunities for biomarker discovery and identification of targets that can lead to patient selection for novel immunostimulatory therapies.

In this recorded webinar, Schalper discusses:

• how his group deciphers the tumor microenvironment and its role in immuno-oncology using highly multiplexed panels
• strategies for validation of multiplexing panels to interrogate diverse tumor and immune cell populations
• the evaluation of antitumor immune responses and biomarker discovery
• results from immunoprofiling with Imaging Mass Cytometry to uncover the immune composition of human non-small cell lung cancer (NSCLC).

Please join us for the webinar and an in-depth Q&A session that follows.

Kurt Schalper, MD, PhD
Assistant Professor of Pathology and Medicine (Medical Oncology)
Director Translational Immuno-Oncology Laboratory
Yale Cancer Center

For Research Use Only. Not for use in diagnostic procedures.

Stanford researchers describe how their integration of CyTOF® mass cytometry analysis with other omic approaches revealed the existence of an immune clock during human pregnancy.

In this recorded webinar, Dr. Brice Gaudilliere, MD, PhD, and Nima Aghaeepour, PhD, both of Stanford University School of Medicine, describe how they characterized the molecular pacemakers of pregnancy by integrating CyTOF® mass cytometry analysis and other omic approaches on blood samples collected throughout pregnancy.

The maintenance of pregnancy relies on a finely tuned immune balance between tolerance to the fetal allograft and protective mechanisms against invading pathogens. Demonstrating the chronology of immune adaptations to a term pregnancy provides the framework for future studies examining deviations implicated in pregnancy-related pathologies including preterm birth and preeclampsia.

Gaudilliere presents data demonstrating that these adaptations are precisely timed, reflecting an immune clock of pregnancy in women delivering at term. An elastic net model with prior Bayesian distributions extracted from literature-based knowledge of the immune was used to develop a predictive model of interrelated immune events that accurately captured the chronology of pregnancy.

Aghaeepour describes how the immunological dataset derived from the mass cytometry analysis was integrated with other omic datasets collected simultaneously at each time point, including data from the transcriptome, microbiome, proteome and metabolome. He also presents a novel computational approach combining all available omic datasets into a predictive model that reveals unique interactions between the different pacemakers of pregnancy.

Presenters

	Dr. Brice Gaudilliere, MD, PhD Assistant Professor, Department of Anesthesiology Stanford University School of Medicine
	Nima Aghaeepour, PhD Assistant Professor Stanford University School of Medicine

For Research Use Only. Not for use in diagnostic procedures.

Watch Chris Linthwaite, President and CEO of Fluidigm, introduce the Hyperion™ Imaging System at the Future of Imaging announcement event held on October 24, 2017, in Toronto, Canada.

During this 90-minute program you will also hear three leading researchers share their insights and experiences with this revolutionary new approach to tissue imaging in the context of their own translational research programs.

Previously viewed live by researchers from around the world, this exciting program is now available to view on-demand.

The Hyperion Imaging System significantly expands the number of protein biomarkers that can be simultaneously detected from tissues and tumors as compared to results from standard fluorescent immunohistochemistry (IHC) methods. With the potential to revolutionize disease research and change the way diseases are treated and ultimately cured in the future, this new approach provides researchers with an unprecedented view of complex cellular phenotypes and their relationships in the context of the tissue microenvironment.

Presenters:

A New View:   
Empowering a Revolution in Tissue Imaging
Chris Linthwaite
President and CEO
Fluidigm

Uncovering Cellular Social Networks: 
Analysis of Tissue Ecosystems in Health 
and Disease by Imaging Mass Cytometry
Bernd Bodenmiller, PhD
Assistant Professor
Institute of Molecular Life Sciences
University of Zurich

Empowering Drug Discovery and Development:
Incorporating Imaging Mass Cytometry into a Multi-Platform Tissue Testing Workflow
Matt Silver, PhD
Principal Scientist
Global Clinical Biomarkers and Companion Diagnostics
EMD Serono

Advancing Translational and Clinical Research:
Imaging Mass Cytometry to Characterize the Tumor Immune Microenvironment   
Akil Merchant, MD
Assistant Professor of Medicine
Keck School of Medicine
University of Southern California

Learn more about how the Hyperion™ Imaging System significantly expands the number of protein markers that can be simultaneously detected in tumors and tissues by Imaging Mass Cytometry™.

More than 200 scientists from around the world gathered in Boston on June 9 for our 6th Annual Mass Cytometry Summit to share research findings, discuss advances and develop new collaborations. We are grateful to the researchers below who have graciously agreed to share their presentations with the mass cytometry community.

Register for the 7th Annual Mass Cytometry Summit.

New Applications

---

A Mass Cytometry Surrogate for Light Scatter
Adeeb Rahman, PhD
Director of Technology Development Human Immune Monitoring Core
Icahn School of Medicine at Mount Sinai Hess Center for Science and Medicine

---

Dynamics of T Lymphocyte Fate Specification Revealed by Tracing Cell Proliferative History
Zinaida Good, PhD
PhD Candidate, Computational and Systems Immunology
Garry P. Nolan and Sean C. Bendall labs Stanford University

---

Extensive Characterization of Autoreactive CD8 T Cells in Type 1 Diabetes
Alice Wiedeman, PhD
Staff Scientist
Human Immunophenotyping Core
Benaroya Research Institute

.innerContainer { position: relative; display: block; width: 100% !important; height: 0; padding: 56.25% 0 0 0; /* This should reflect your video aspect ratio */} .outerContainer { max-height: 360px; /* Set this to the height of your player */} .vidyard_player { position: absolute; top: 0; left: 0; width: 100%; height: 100%; max-width: 640px; /* These should be the dimensions of your player */ max-height: 360px;} .vidyard_player > span { width: 100% !important; height: 100% !important; margin: 0 auto !important;}

Best Practices and Data Analysis

---

Panel Design Optimization through the Designed Distribution of Signal Interference
Bill O’Gorman, PhD
Genetech

.innerContainer { position: relative; display: block; width: 100% !important; height: 0; padding: 56.25% 0 0 0; /* This should reflect your video aspect ratio */} .outerContainer { max-height: 360px; /* Set this to the height of your player */} .vidyard_player { position: absolute; top: 0; left: 0; width: 100%; height: 100%; max-width: 640px; /* These should be the dimensions of your player */ max-height: 360px;} .vidyard_player > span { width: 100% !important; height: 100% !important; margin: 0 auto !important;}

---

Computational Strategies for Mass Cytometry Data Analysis
Nikolay Samusik, PhD
Research Scientist Garry P. Nolan Lab
Stanford School of Medicine

---

A New Analytic Approach for Live Singlet Identification
Bruce Bagwell, MD, PhD
President, Verity Software House

---

Cytobank Solutions
Vinko Tosevki, PhD
Scientist, Head of Mass Cytometry Facility University of Zurich

Read more about the 6th Annual Mass Cytometry Summit

Want to learn more about mass cytometry?
Provide us with your contact information below.

For Research Use Only. Not for use in diagnostic procedures.

Enabling high-parameter studies, mass cytometry has quickly become a mainstay in basic and translational research laboratories around the world. In this video researchers share how mass cytometry is powering new insights in health and disease.

Researchers identify a unique population of pathologic CD4+ T cells in both blood and synovial fluid using mass cytometry

In this video, Dr. Deepak Rao, MD, PhD, of Brigham and Women’s Hospital presents his recent research using mass cytometry and multidimensional flow cytometry to identify key pathologic T cell populations in the synovial fluid of subjects with rheumatoid arthritis.

Determining the pathologic functions of T cells that infiltrate target tissues remains a central challenge in autoimmune diseases. In this video, Dr. Deepak Rao, MD, PhD, of Brigham and Women’s Hospital describes recent work, published in Nature, identifying a unique population of pathologic CD4⁺ T cells, called T peripheral helper (T_PH) cells, that is markedly expanded in the joints of subjects with rheumatoid arthritis (RA). Rao and colleagues used mass cytometry and multidimensional flow cytometry to interrogate T cell populations in synovial tissue and blood from research subjects with RA, a chronic immune-mediated arthritis that affects up to 1% of the population.

Mass cytometric analysis of RA synovial tissue cells revealed a strikingly expanded population of PD-1^hiCXCR5^-CD4⁺ T cells, which constituted ~25% of synovial CD4⁺ T cells. Surprisingly, these cells are not exhausted, but instead highly express factors enabling B cell help, including IL-21, CXCL13, ICOS, SAP and MAF. Like T follicular helper (T_FH) cells, PD-1^hiCXCR5^- cells from synovium and blood induce plasma cell differentiation in vitro via IL 21. However, RNA-seq transcriptomics robustly separates PD-1^hiCXCR5^- cells from T_FH cells, with altered expression of Bcl6 and Blimp-1 and unique expression of chemokine receptors that direct migration to inflamed sites, such as CCR2, CX3CR1 and CCR5, in PD-1^hiCXCR5^- cells.

Rao and colleagues propose that PD-1^hiCXCR5^- T cells represent a T_PH cell population, analogous to T_FH cells, that supports B cell responses in pathologically inflamed nonlymphoid tissues. Given their marked expansion in RA joints, these cells may be important in driving pathologic B cell responses and autoantibody production within the inflamed target tissue.

Michelle Poulin, PhD, of Fluidigm provides a brief overview of mass cytometry, the high-parameter, single-cell analysis technology used by Rao in his research.

Speakers

Dr. Deepak Rao, MD, PhD   
Rheumatologist   
Co-Director, Human Immunology Center    
Brigham and Women's Hospital 
Boston, MA

Michelle Poulin, PhD
Applications Scientist
Fluidigm Canada Inc. 
Markham, ON, Canada

fluidigm

For Research Use Only. Not for use in diagnostic procedures.